GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Dutasteride-Test product
Drug: Dutasteride-Reference product

First Posted Date: 2015-10-19

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02578953

Locations: 🇯🇵
GSK Investigational Site, Fukuoka, Japan

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Batefenterol + Fluticasone Furoate
Drug: Placebo
Drug: Albuterol

First Posted Date: 2015-10-12

Last Posted Date: 2020-07-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 63

Registration Number: NCT02573870

Locations: 🇺🇸
GSK Investigational Site, McKinney, Texas, United States

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Batefenterol
Drug: Umeclidinium/ Vilanterol
Drug: Placebo

First Posted Date: 2015-10-07

Last Posted Date: 2019-07-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 325

Registration Number: NCT02570165

Locations: 🇿🇦
GSK Investigational Site, Thabazimbi, South Africa

A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.

Phase 3

Completed

Conditions: Chicken-pox Illness (Varicella Virus Disease)
Chickenpox

Interventions: Biological: Varilrix™
Biological: Varilrix HSA-free

First Posted Date: 2015-10-07

Last Posted Date: 2019-11-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1236

Registration Number: NCT02570126

Locations: 🇬🇧
GSK Investigational Site, Southampton, United Kingdom

A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia

Not Applicable

Completed

Conditions: Dengue

Interventions: Procedure: Blood sample collection

First Posted Date: 2015-10-07

Last Posted Date: 2020-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2004

Registration Number: NCT02570152

Locations: 🇱🇰
GSK Investigational Site, Colombo, Sri Lanka

Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.

Completed

Conditions: Acellular Pertussis
Tetanus
Aspergillosis, Allergic Bronchopulmonary
Diphtheria
Diphtheria-Tetanus-acellular Pertussis Vaccines

Interventions: Other: Pertussis maternal immunization

First Posted Date: 2015-10-07

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02569879

Locations: 🇨🇴
GSK Investigational Site, Bogota, Colombia

Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age

Completed

Conditions: Acute Otitis Media
Pneumonia

Interventions: Other: Data collection

First Posted Date: 2015-10-05

Last Posted Date: 2019-06-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02567747

Locations: 🇨🇴
GSK Investigational Site, Bogota, Colombia

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

Phase 1

Completed

Conditions: Cachexia

Interventions: Drug: Placebo
Drug: GSK2881078
Drug: Itraconazole

First Posted Date: 2015-10-05

Last Posted Date: 2017-03-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 108

Registration Number: NCT02567773

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK2269557 DPI
Drug: Placebo DPI

First Posted Date: 2015-10-05

Last Posted Date: 2018-08-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 50

Registration Number: NCT02567708

Locations: 🇩🇪
GSK Investigational Site, Magdeburg, Germany

Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)

Completed

Conditions: Influenza

Interventions: Other: Vaccine safety surveillance

First Posted Date: 2015-10-05

Last Posted Date: 2016-02-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 11530

Registration Number: NCT02567721

Locations: 🇬🇧
GSK Investigational Site, Surrey, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy